Cys24-Glu188
17 kDa (Reducing)
20mM Tris, 300mM NaCl, pH8.0
Reconstitute at 0.1-1 mg/ml according to the size in ultrapure water after rapid centrifugation.
·12 months from date of receipt, lyophilized powder stored at -20 to -80℃.
·3 months, -20 to -80℃ under sterile conditions after reconstitution.
·1 week, 2 to 8℃ under sterile conditions after reconstitution.
·Please avoid repeated freeze-thaw cycles.
Molecules. 2020 Aug 31;25(17):3965.
Biomark Res. 2022 Sep 14;10:69.
Interferon-alpha 2b (IFN-α2b) is a subtype of type I interferons (IFNs), which are a group of cytokines with antiviral, antiproliferative, and immunomodulatory functions. The human IFN-α family comprises 13 genes encoding 12 proteins, and all IFN-αs bind to a common receptor (IFNAR1/IFNAR2) to exert their effects. IFN-α2b is one of the most extensively studied IFN-α subtypes due to its high activity and availability for research. It was the first highly active IFN subtype to be cloned and has been widely used in fundamental research and clinical applications. IFN-α2b signals through the Janus kinase (JAK) and signal transducer and activator of transcription (STAT) pathway, leading to the activation of various interferon-stimulated genes (ISGs) that contribute to its antiviral and other biological activities.
IFN-α2b is FDA-approved for treating malignancies such as melanoma, renal cell carcinoma, and hematologic cancers (e.g., hairy cell leukemia). Its direct antitumor effects include inducing apoptosis and suppressing proliferation, while indirect effects involve immune activation (e.g., enhancing NK cell activity). It is also widely used against chronic hepatitis B and C, SARS-CoV, and other viral infections by blocking viral replication and modulating immune responses
Primary antibody: IFIT1 Recombinant Rabbit mAb (S0B1242) at 1/1000 dilution
Lane 1: untreated HeLa whole cell lysate 20 µg
Lane 2: HeLa treated with 10 ng/ml IFN-α2b(UA040399) for 16 hours whole cell lysate 20 µg
Secondary antibody: Goat Anti-rabbit IgG, (H+L), HRP conjugated at 1/10000 dilution
Predicted MW: 55 kDa
Observed MW: 58 kDa
Measured in anti-viral assays using HeLa human cervical epithelial carcinoma cells infected with encephalomyocarditis (EMC) virus. The EC50 for this effect is less than 60 pg/ml.
Measured by a cytotoxicity assay using TF-1 Cells, The ED50 for this effect is less than 0.8ng/ml.
2μg (R: reducing condition, N: non-reducing condition).
>90% as determined by RP-HPLC.
您现在的位置：
